News: Jetzt kanns losgehen - 500 Beiträge pro Seite

[pblack]

RNS ist gerade raus und schon auf AFXF - London 20% plus vom Tief


Partnership with Major Pharma

RNS Number:7070P
Cytomyx Holdings PLC
04 August 2005


For Immediate Release 4 August 2005



Cytomyx further expands ion channel cell line capabilities with
a worldwide co-exclusive license agreement
with Wyeth Pharmaceuticals


Validated Ion Channel cell lines for Kv4.3 and the four KChIP accessory sub-unit
proteins are now available from Cytomyx


Cytomyx Ltd (Cambridge, UK), a division of Cytomyx Holdings, PLC (AIM:CYX.L), a
leading provider of drug discovery products and services, is pleased to announce
that it has signed a worldwide co-exclusive license agreement with Wyeth
Pharmaceuticals (PA, USA) which allows Cytomyx to create and market cell lines
expressing the ion channel, Kv4.3 , and the four KChIP accessory sub-units as
research reagents for use in drug discovery and safety pharmacology screening.
Wyeth holds the patents and patent applications relating to the ion channels
Kv4.3, and the four KChIP accessory sub-units.

The validated cell lines can also be accessed via Cytomyx` unique IonScreenTM,
Ion Channel Screening Service. The service combines Cytomyx` unparalleled range
of validated ion channel cell lines with its expertise in automated
electrophysiology to deliver timely, high quality data.



This strategically important agreement expands further the unique ion channel
cell line and screening service portfolio offered by Cytomyx to pharmaceutical
and biotechnology clients worldwide. Currently the company has 18 validated ion
channel cell lines available and 50 more are in development. Cytomyx continues
to be the industry leader for ion channel related products and services and has
seven out of the top ten pharmaceutical companies as clients to date.



Kv4.3 and the four KChiP accessory sub-units are important targets for drug
discovery and safety pharmacology because they combine in different ways in
different tissues to make a significant contribution to regulating the
electrical activity of the brain and the heart. This regulation can be
disturbed by diseases, is at the core of learning and memory and can be the
cause of the side effects of medicines.



In consideration of the license Wyeth Pharmaceuticals will access know-how and
validated cell lines from Cytomyx, enabling them to progress internal drug
screening and safety pharmacology programs.



-Ends-


For Further Information Contact:

Cytomyx Tel: [phone]
6-7 Technopark, Cambridge, CB5 8PB, UK. Fax: [phone]

Mike Kerins, CEO,
Email: [e-mail]
Web: www.cytomyx.com

Wyeth Pharmaceuticals, Tel: [phone]
500 Arcola Road, Collegeville, PA, 19426, USA Fax: [phone]

Christine Foster, Senior Director, Licensing,
Email: [e-mail]
Web: www.Wyeth.com

Buchanan Communications Tel: [phone]
107 Cheapside, London EC2V 6DN Fax: [phone]

Mark Court, Director
Mary-Jane Johnson, Account Director







Note to Editors

About Cytomyx Holdings

Cytomyx Holdings plc is a rapidly growing life science company based in
Cambridge, UK. The Company`s primary focus is on developing novel technologies
that assist pharmaceutical and biotechnology companies in their efforts to
develop new treatments more effectively. The company does this by providing
solutions that provide early insights into the likely efficacy and safety
profile of new drugs in development. The Company has two main areas of
expertise: the use of human clinical samples in understanding the linkage
between gene expression and disease and the development of cell-based assays
that are used to support ion channel drug discovery and predict potential
cardiac toxicity in new drugs. Cytomyx is listed on the AIM market of the
London Stock Exchange (CYX.L). For more information visit
www.cytomyx-holdings.com






This information is provided by RNS
The company news service from the London Stock Exchange
END

NRABLGDICUGGGUX



Hier online taxe aus London Offer bei 13 Pence = 0,19 Cent



Allen Good luck

[pblack]

Hier die Pressemeldung

Cytomyx in license deal with Wyeth Pharmaceuticals

LONDON (AFX) - Cytomyx Holdings PLC said it has signed a worldwide co-
exclusive license agreement with Wyeth Pharmaceuticals in the US which allows
Cytomyx to create and market cell lines expressing the ion channel, Kv4.3, and
the four KChIP accessory sub-units as research reagents for use in drug
discovery and safety pharmacology screening.
Wyeth holds the patents and patent applications relating to the ion channels
Kv4.3, and the four KChIP accessory sub-units.
[e-mail]
slm/

COPYRIGHT

Copyright AFX News Limited 2005. All rights reserved.

The copying, republication or redistribution of AFX News content, including by
framing or similar means, is expressly prohibited without the prior written
consent of AFX News.

AFX News and the AFX Financial News logo are registered trademarks of AFX News
Limited

[pblack]

fettes volumen in London

[pblack]

Volumen steigt weiter in London (siehe chart oben)

Last RT 12,8 Pence = 18,6 Cent

[pblack]

[pblack]

volumen passt - keiner lust?

[schakal23]

warum sind die wider gefallen heute?